NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Valuation After China GLP‑1 Expansion And Tirzepatide Safety Push
Eli Lilly (LLY) is back in focus after outlining a US$3b, decade-long investment in China tied to its oral GLP-1 drug orforglipron, while separately pressing U.S. regulators on compounded tirzepatide safety.
See our latest analysis for Eli Lilly.
Despite a series of obesity drug launches, access initiatives, legal headlines and this new US$3b China plan, Eli Lilly’s short term share price performance has cooled. The company has seen a 30 day share price decline of 5.28% and a year to date...